Neurobiology of Pain Laboratory, Departamento de Farmacobiología, Cinvestav, Mexico City, Mexico.
Facultad de Biología, Universidad Autónoma de Sinaloa, Culiacán, Mexico.
Pain. 2023 May 1;164(5):948-966. doi: 10.1097/j.pain.0000000000002763. Epub 2022 Aug 24.
The loss of GABAergic inhibition is a mechanism that underlies neuropathic pain. Therefore, rescuing the GABAergic inhibitory tone through the activation of GABA A receptors is a strategy to reduce neuropathic pain. This study was designed to elucidate the function of the spinal α 6 -containing GABA A receptor in physiological conditions and neuropathic pain in female and male rats. Results show that α 6 -containing GABA A receptor blockade or transient α 6 -containing GABA A receptor knockdown induces evoked hypersensitivity and spontaneous pain in naive female rats. The α 6 subunit is expressed in IB4 + and CGRP + primary afferent neurons in the rat spinal dorsal horn and dorsal root ganglia but not astrocytes. Nerve injury reduces α 6 subunit protein expression in the central terminals of the primary afferent neurons and dorsal root ganglia, whereas intrathecal administration of positive allosteric modulators of the α 6 -containing GABA A receptor reduces tactile allodynia and spontaneous nociceptive behaviors in female, but not male, neuropathic rats and mice. Overexpression of the spinal α 6 subunit reduces tactile allodynia and restores α 6 subunit expression in neuropathic rats. Positive allosteric modulators of the α 6 -containing GABA A receptor induces a greater antiallodynic effect in female rats and mice compared with male rats and mice. Finally, α 6 subunit is expressed in humans. This receptor is found in CGRP + and P2X3 + primary afferent fibers but not astrocytes in the human spinal dorsal horn. Our results suggest that the spinal α 6 -containing GABA A receptor has a sex-specific antinociceptive role in neuropathic pain, suggesting that this receptor may represent an interesting target to develop a novel treatment for neuropathic pain.
GABA 能抑制的丧失是导致神经性疼痛的一种机制。因此,通过激活 GABA A 受体来恢复 GABA 能抑制性张力是减轻神经性疼痛的一种策略。本研究旨在阐明脊髓 α6 包含 GABA A 受体在雌性和雄性大鼠生理条件和神经性疼痛中的功能。结果表明,α6 包含 GABA A 受体阻断或瞬时 α6 包含 GABA A 受体敲低会在未受伤的雌性大鼠中引起诱发性过敏和自发性疼痛。α6 亚基在大鼠脊髓背角和背根神经节中的 IB4+和 CGRP+初级传入神经元中表达,但不在星形胶质细胞中表达。神经损伤会降低初级传入神经元和背根神经节中中枢末端的 α6 亚基蛋白表达,而鞘内给予 α6 包含 GABA A 受体的正变构调节剂可减轻雌性而非雄性神经性大鼠和小鼠的触觉过敏和自发性疼痛行为。脊髓 α6 亚基的过表达可减轻触觉过敏并恢复神经性大鼠中的 α6 亚基表达。α6 包含 GABA A 受体的正变构调节剂在雌性大鼠和小鼠中引起的抗痛觉过敏作用大于在雄性大鼠和小鼠中。最后,α6 亚基在人类中表达。该受体存在于人类脊髓背角的 CGRP+和 P2X3+初级传入纤维中,但不存在于星形胶质细胞中。我们的结果表明,脊髓 α6 包含 GABA A 受体在神经性疼痛中具有性别特异性的镇痛作用,表明该受体可能是开发神经性疼痛新治疗方法的一个有趣靶点。